Lipodystrophy Clinical Trial
Official title:
A Phase IV, Prospective, Non-Blinded, Non-Randomized, Single-Center Clinical Trial to Determine the Longevity, Duration, and Volume-Correcting Efficacy of Sculptra™ Dermal Filler for the Correction of Contour Deformities Caused by Lipoatrophy
Lipoatrophy is a condition that affects certain individuals, most commonly those who are
infected with the HIV virus. Lipoatrophy however can also affect individuals who suffer from
recurrent systemic infections, those who have a weakened immune system, or certain patients
who suffer from cancer or receive chemotherapeutics. In contrast, lipoatrophy can sometimes
be present in individuals who are perfectly healthy but have genetically predisposing
factors that can contribute to facial emaciation or lipoatrophy.
The function of injectable fillers for the treatment of dermal contour deformities is to
smooth dermal depressions formed by the loss of volume. These often elastic contour fillers
(also known as soft tissue augmentation devices) can correct hollowness around the eyes, add
fullness to thin lips, balance a disproportionate face or correct topographical anomalies.
This study aims to:
- Objectively measure the improvement of contour-deformities after Sculptra™ injection
from baseline to study closure by utilizing the Primos™ photographic/topographical
measuring system.
- Evaluate the efficacy, longevity and duration of volume-correction in subjects which
are both HIV positive and HIV negative.
- Assess the safety of Scupltra™ dermal filler when used to correct volume deformities
caused by lipoatrophy in subjects that are HIV negative.
Soft tissue fillers are used to temporarily fill facial lines and wrinkles and augment
contour deformities. There are a variety of soft tissue fillers available.
Sculptra™ has been used to correct dermal atrophy in both the HIV and non-HIV populations.
Almost all clinical trials have used a visual assessment scale to grade correction as well
as persistence. Recently, dermal ultrasound has been used to provide an objective
measurement of dermal thickening, but the ultrasound procedure measures only a fraction of
the dermis and is subject to a high degree of variability because of the difficulty in
measuring the same area. Our protocol utilizes the Primos ½ face system to produce a
3-dimensional evaluation of a large area. This will produce excellent reproducible results
as well as outstanding photographs for patient demonstration.
Sculptra™ is an injectable implant that contains microparticles or poly-L-lactic acid, a
biocompatible, biodegradable, synthetic polymer from the alpha-hydroxy-acid family.
Sculptra™ is reconstituted prior to use by the addition of sterile water for injection, USP
(SWFI) to form a sterile non-pyrogenic suspension.
Comparison:
Dermik's Vega Study - The Vega study was a 96-week, open-label, uncontrolled, single-center
study to determine the treatment effects of Sculptra on the signs of lipoatrophy of the face
in 50 patients infected with human immunodeficiency virus. Patients had a mean age of 45
years (range 33-58), 84% were Caucasian and 98% were male. All patients had little or no
adipose tissue in cheek area at baseline, indicating severe facial lipoatrophy (mean adipose
thickness of 0.5±0.7 mm, ranging from 0.0 to 2.1 mm).
Treatment injection sessions were conducted at approximately two-week intervals, and the
majority (86%) of the patients received four to five injection sessions. Generally, one vial
of product was injected intradermally into multiple points of each cheek at each injection
session. The quantity of injected product and number of injection sessions depended upon the
severity of the facial depression.
All patients experienced increases in skin thickness in the treatment area (minimum increase
of 2.2 mm noted at Week 8 visit). Statistically significant increases above baseline values
of mean skin thickness were noted at all time points (Weeks 8, 24, 48, 72 and 96) during the
study. Increases in mean skin thickness changes above baseline persisted for up to 2 years.
This study follows the same general design as the Vega study.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05419037 -
Natural History of Pregnancy and Pregnancy Outcomes in Metreleptin-Treated vs Untreated Subjects With Lipodystrophy
|
||
Recruiting |
NCT03059121 -
The Cleveland Cardiometabolic Cohort
|
||
Completed |
NCT00656175 -
Raltegravir Therapy for Women With HIV and Fat Accumulation
|
Phase 2 | |
Completed |
NCT00006185 -
Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome
|
Phase 1 | |
Completed |
NCT00202241 -
The Effects of Anabolic Steroids and Protease Inhibitors on People Living With HIV/AIDS
|
N/A | |
Recruiting |
NCT02262832 -
Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
|
Phase 3 | |
Completed |
NCT01679197 -
Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy
|
Phase 2 | |
Completed |
NCT02647853 -
Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT00715546 -
Autologous Adipose-Derived Stem Cell Transplantation in Patients With Lipodystrophy
|
Phase 1 | |
Completed |
NCT00069004 -
A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth
|
N/A | |
Completed |
NCT00025883 -
Leptin to Treat Lipodystrophy
|
Phase 2 | |
Completed |
NCT00001142 -
Metabolism and Body Shape of Healthy Children and Children With Chronic Infections
|
N/A | |
Active, not recruiting |
NCT02262806 -
Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy
|
Phase 2 | |
Completed |
NCT02258685 -
Factors Mediating Gut Microbiota Dysbiosis and Metabolic Disease in HIV Patients.
|
||
Completed |
NCT00192621 -
Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects
|
Phase 4 | |
Completed |
NCT00006190 -
A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy
|
Phase 4 | |
Recruiting |
NCT05930106 -
Carotid Doppler Peak Velocity Variation in Liposuction Fluid Management
|
N/A | |
Completed |
NCT00004329 -
Study of Alpha-2 Adrenergic Receptor Dysfunction in Regional Lipoatrophy
|
N/A | |
Recruiting |
NCT04656054 -
Hemoglobin Level, Coagulopathy Profile and Electrolyte Balance
|
||
Completed |
NCT00082628 -
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
|
Phase 3 |